SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Fears of a Democratic sweep in the U.S. midterms dominate QQQ discussion, with traders attributing volatile Nasdaq selling to concerns about tech and AI regulation, including data-center scrutiny. Others call the reaction an overreaction because the outcome was widely expected and see the dip as a buying opportunity.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Midterm election returns and perceived Democratic gains dominate discussion, with traders debating whether a setback for Trump and Republicans could weigh on the Trump-linked stock. Bearish posts predict selling, while supporters argue the results are uncertain or reflect a typical midterm pattern.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs quarterly earnings beat and stronger-than-expected outlook, driven by surging AI data-center demand, are fueling a sharp post-results move and renewed optimism about growth. Traders remain divided over whether the rally can hold, with concerns about valuation, weaker cash flow and inventory, and reliance on data-center spending tempering the bullish reaction.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A rebound in semiconductor shares, supported by strong AMD and SMCI earnings and renewed optimism about AI demand, is lifting SOXL after steep recent losses. Traders are divided between viewing the move as a relief rally and warning that election uncertainty, tech-sector selling, and the funds 3x leverage could keep volatility high.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros stronger-than-expected quarterly results and raised full-year outlook, attributed to robust AI-server demand, are driving attention. Many traders view the growth as bullish, while others question whether thin margins, cash-flow pressures and lingering doubts about management justify the muted share-price reaction.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a sharp neocloud and AI-infrastructure selloff, with traders worried that a Democratic midterm sweep could bring tighter limits on data-center development; concerns about debt financing and whether AI demand will justify heavy investment are adding pressure. The community is split between expecting an oversold rebound ahead of earnings and warning that funding risks and weak sector sentiment could drive further losses.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

AMDs strong results and outlook are fueling a semiconductor rebound, with traders treating them as evidence that AI-chip demand remains resilient ahead of Nvidias earnings. The optimism is tempered by election-related concerns about AI policy and by debate over whether Nvidias bounce can hold after recent selling.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles large stock-and-bond financing for its AI data-center buildout is driving debate: many traders worry about dilution, borrowing costs and whether AI spending will generate enough cash flow, while others see the completed raise as removing a funding overhang. The stocks rebound has prompted talk of a possible reversal or short squeeze, though skepticism about its financing and execution risks remains.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

A Q3 revenue miss and concerns about buildout costs and financing have fueled sharp swings in CIFR. Bulls point to its first HPC lease revenue and longer-term data-center contracts, while skeptics question execution and dilution and some traders attribute the rebound to an oversold bounce or short covering.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Election-related uncertainty is driving the discussion, with traders speculating that Democratic gains could bring greater scrutiny of Musk and SpaceX or threaten government contracts; others argue the companys business is resilient and the political fears are overblown. The debate is adding to volatility, alongside bullish and bearish views on the stocks direction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can-Fite’s Liver Cancer Trial Just Got More Interesting and the FDA Clock Matters Now

Can-Fite BioPharma (NYSEAMERICAN:CANF) has put a potentially important new marker on the radar for its late-stage liver-cancer program: patients in the company’s ongoing pivotal Phase III study of Namodenoson are living longer than anticipated across the blinded study population.

AI, Clinical Data, and Regulatory Catalysts have Wall Street Watching These Biotechs

Three emerging biotechnology companies, Can-Fite BioPharma (NYSEAMERICAN:CANF), NeOnc Technologies (NASDAQ:NTHI), and PMGC Holdings (NASDAQ:ELAB) through its NorthStrive Biosciences subsidiary, are pursuing a distinct therapeutic strategy, the common theme is execution. Clinical data, regulatory milestones, AI-assisted discovery platforms, and expanding development pipelines are creating a steady stream of catalysts that investors will be watching closely during the second half of 2026.

Why Is CANF Stock Surging Today?

Equity

Can-Fite said Namodenoson met the Phase IIa study's main safety goal and demonstrated durable overall survival.

CANF Stock Pulls Back After Patent-Fueled Surge – Retail Calls It Consolidation Ahead Of Next Leg Up

Can-Fite BioPharma announced it has received a patent in Japan for its obesity therapy.

CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data

Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.

Power, Compute and Breakthrough Science

Today’s headlines underscore a decisive shift toward owning the infrastructure, power, and materials that will underpin the next phase of the AI economy, including $KBLB, $VCIG, $CANF, $ASNS, $BW, and $APLD

Why Did CANF Stock Soar 25% Today?

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

This Microcap Just Locked Up New IP in a Massive Pharma Market

In biotechnology, intellectual property wins often act as quiet but powerful catalysts, particularly when they extend a platform into new therapeutic categories or unlock access to large international markets. As competition intensifies and pipelines mature, patent protection remains a key driver of long-term value, especially for companies advancing novel mechanisms with broad clinical applicability.Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF) are surging Friday after the company announced it was granted a new patent in Brazil covering the treatment of sexual dysfunction. The ...

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Can-Fite Biopharma Ltd - ADR

Neutral Sentiment

<ul class="summary-bullets"><li>The company enrolled 20 patients with advanced pancreatic ductal adenocarcinoma for the Namodenoson study.</li><li>It noted that the median survival exceeded five months among the eight evaluable patients receiving the treatment as their third option.</li><li>Can-Fite now plans to initiate a Phase 2b study combining the treatment with chemotherapy.&nbsp;&nbsp;&nbsp;</li></ul><p>Shares of Can-Fite BioPharma (CANF) surged on Wednesday after the company announced positive early-stage study results for its treatment targeting pancreatic tumors.</p><p>At the time of writing, CANF shares were up more than 50%, reaching their highest level in nearly three months.</p><h2 class="st-heading-2"><strong>Can-Fite’s Study Results</strong></h2><p>The company enrolled 20 patients with advanced pancreatic ductal adenocarcinoma, a type of hard-to-treat cancer that begins in the digestive tract of the pancreas and is not noticeable during the early stages.</p><p>In its Phase IIa study evaluating Namodenoson, 14 patients received the therapy as their third-line treatment, five as their second-line treatment, and one as their fourth-line treatment. Can-Fite said Namodenoson met the study's main safety goal and demonstrated durable overall survival. It was also well tolerated and displayed a safety profile consistent with prior trials.</p><h2 class="st-heading-2"><strong>Next Steps For Can-Fite</strong></h2><p>Among other things, the company noted that the median survival exceeded five months among the eight evaluable patients receiving the treatment as their third option and, as a result, plans to initiate a Phase 2b study combining the treatment with chemotherapy. &nbsp;</p><p>“Pancreatic cancer remains one of the most difficult malignancies to treat, particularly after failure of standard therapies,” said Prof. Salomon Stemmer, who is spearheading the company’s study. “The results of Namodenoson monotherapy are impressive, and the favorable safety profile together with the prolonged survival observed in a subgroup of patients suggest biological activity worthy of further investigation.”</p><h2 class="st-heading-2"><strong>What Retail Traders Think About CANF</strong></h2><p>On Stocktwits, retail sentiment toward the stock turned ‘extremely bullish’ from ‘bullish over the last 24 hours.</p><p><a href="https://stocktwits.com/symbol/CANF">CANF shares</a> have fallen roughly 26% so far this year and about 86% over the past 12 months, underperforming the benchmark S&amp;P index.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Rising stock market chart on a trading board background. (Source: Getty Images)

Shares of Can-Fite BioPharma (CANF) surged on Wednesday after the company announced positive early-stage study results for its treatment targeting pancreatic tumors.

Current Price	$1.62
Prev Close	$1.63
Open	$1.65
Dividend Yield	0.00%
50-Day Moving Average	$2.19
Beta	0.57
Avg. Volume	66,748.08
PE Ratio	-0.26

52-Week High	$12.30
52-Week Low	$1.60
Market Capitalization	$4.92M
EPS (Annual)	-$12.03
Price to Book	0.71
Revenue Per Employee	$81,642.60

Feed

News

Sentiment

Fundamentals

Info

CANF Fundamentals